The newest developments of the study on anti-HIV drugs / 药学学报
Acta Pharmaceutica Sinica
;
(12): 509-515, 2015.
Article
in Chinese
| WPRIM
| ID: wpr-251749
ABSTRACT
Besides 36 (28 single-tablets and 8 fixed-dose combinations) used antiretroviral drugs clinically, there are a number of investigational antiretroviral agents currently in phase 2-3 clinical trial. Tenofoviralafenamidefumarate (TAF) is a novel nucleoside analogue reverse transcriptase inhibitor that is potent and less toxicity than tenofovir (TDF). Doravirine is a non-nucleoside analogue reverse transcriptase inhibitor that demonstrates activity against NNRTI-resistant viral strains. GSK744 is an integrase inhibitor with a long acting preparation. In addition, several drugs with new mechanisms are also noted, for example, BMS-663 068 is a small molecule CD4 attachment inhibitors and cenicriviroc is a novel CCR5/CCR2 antagonist with antiretroviral activity and anti-inflammatory effects. Several drug classes that target known pathways in HIV latency have being developed, and leading the list are histone deacetylase inhibitors. Other agents include protein kinase C activators, positive transcription elongation factor activators, DNA methyl-transferase inhibitors and histone methyl-transferase inhibitors and so on. This review is focused on the above-mentioned drug candidates that may be used in clinical in next couple of years and those compounds that can reverse latent HIV infections.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Organophosphates
/
Piperazines
/
Pyridones
/
Adenine
/
HIV Infections
/
Reverse Transcriptase Inhibitors
/
Anti-HIV Agents
/
Therapeutic Uses
/
Drug Therapy
/
Organophosphonates
Limits:
Humans
Language:
Chinese
Journal:
Acta Pharmaceutica Sinica
Year:
2015
Type:
Article
Similar
MEDLINE
...
LILACS
LIS